• Subscribe
  • Advertise
  • About us
  • Follow
  • Follow
  • Follow
  • Follow
Pharmafile Logo
  • Magazine
    • PharmaTimes Magazine Archive
  • Web Exclusives
  • News
  • Competitions
  • Appointments
  • Business Insights
  • Webinars
  • Thought Leadership

Venn launches innovation division for co-development

by PharmaTimes | 1st Jan 2000 | News

Tags


Related posts

HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours

HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours

Mar 4, 2026

Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study

Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study

Mar 4, 2026

AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays

AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays

Mar 3, 2026

Quell launches chill phase 1/2 trial for novel cartreg therapy

Quell launches chill phase 1/2 trial for novel cartreg therapy

Mar 3, 2026

News alerts

This field is required.

Latest content

  • HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
  • Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
  • AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
  • Quell launches chill phase 1/2 trial for novel cartreg therapy
  • Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M

Contact details

PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN

E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999

Get the latest pharma news delivered to your inbox

A valid email address is required.

Download our apps

Go to the App Store or Google Play and search for ‘PharmaTimes’ to download our free app.

Content

News
Magazine
Advertise
Contact
Competitions

Connect

  • Follow
  • Follow
  • Follow
  • Follow
  • Follow

Legal

Privacy Policy
Terms and Conditions
Editorial policy
Cookies
RSS – feed subscriptions
© Copyright PharmaTimes Media Limited 2026